Marisa Wexler, MS, senior science writer —

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

Inhaled TAVT-135 shows promise as treatment for all CF types

TAVT-135, an inhaled treatment candidate being developed for people with cystic fibrosis (CF) regardless of their underlying mutation type, was found to help normalize mucus production in a cell model of the disease. According to researchers from Tavanta Therapeutics, the treatment’s developer, the findings of their in vitro…

Scientists in NYC aim to increase diversity in CF clinical trials

Scientists in New York are calling on the cystic fibrosis (CF) research community to take proactive steps to increase diversity in clinical trials — which now typically include a disproportionate number of non-Hispanic white people, and fewer patients from other racial and ethnic backgrounds. “Ensuring that pwCF [people with…

Antioxidants may help improve CF exercise capacity: Study

High blood sugar can impair the ability to utilize oxygen for energy with cystic fibrosis (CF), which may explain why exercise can be especially tiring for those with the disease, a new study shows. Researchers think the biological mechanism responsible for this phenomenon is that high blood sugar can…

Sale of wound care platform will benefit CF research

30 Technology has sold the rights to its antimicrobial treatment platform for certain uses, such as for burns and acute wounds, to Convatec. 30 Technology will retain the rights to its wound care platform in other indications, including respiratory diseases such as cystic fibrosis (CF), and will be…